Dr. Paul Song has ~30 years of expertise in biotherapeutics drug discovery and development, specializes in immunology and oncology indications. He currently serves as the CSO at GeneQuantum (GQ) Healthcare in Suzhou, China, overseeing R&D efforts, including new target discovery and innovative next generation bioconjugate (ADC) pipeline development. Previously, he held prominent roles such as CSO at Curon Biopharma in Shanghai, China, Vice President at Samsung Bioepis in Seoul, Korea, and Principal Research Scientist at Lilly Research Laboratories in Indianapolis, USA. Dr. Song played an important role in building Samsung Bioepis as a global leader in the biosimilar industry during his tenure. He co-founded Curon Bio, a bioventure focused on advancing next-generation immune-oncology therapeutics. He has a Ph.D. in Biology from Purdue University, USA.